论文部分内容阅读
庆大霉素生产菌棘状小单孢菌耐受无机磷突变株Ｍ，ｅｃｈｉｎｏｓｐｏｒａＭｕｔａｎｔ１２９－Ｐ１产生一种新的氨基糖苷抗生素复合物ＧＰ，经分离纯化获两个单组分ＧＰＡ和ＧＰＢ。研究结果证明抗生素ＧＰＢ与紫色小单孢菌突变株Ｍ．ＰｕｒｐｕｒｅａＪＩ２０所产生的抗生素ＪＩ－２０日同质，抗生素ＧＰＡ与相模湾小单孢菌突变株Ｍ．ｓａｇａｍｉｅｎｓｉｓＮＲＲＬ１１００６０／３１生物转化的产物抗生素ＴＰＪ－Ｂ同质。抗生物ＧＰＡ和ＧＰＢ的抗菌谱广，除对绿脓假单孢菌外，均具有与庆大霉素相近的抗革兰氏阳性和阴性细菌的生物活性。对小鼠的急性毒性比庆大霉素低，体内治疗效果明显比庆大霉素好。ＧＰＡ和ＧＰＢ有协同抗细菌作用。
Gentamicin-producing bacteria Micromonospora sp. Toxin M, echinospora Mutant129-P1, is a new aminoglycoside antibiotic complex GP. Two single-component GPA and GPB were isolated and purified. The results show that the antibiotic GPB and Micromonospora mutans M strain. The antibiotic JI-20 daily standard produced by Purpurea JI20, the antibiotic GPA, and the M. miniemonicum mutant M. The biotransformed product antibiotic TPJ-B is homogenous with sagamiensis NRRL110060 / 31. Antibiotics GPA and GPB wide antibacterial spectrum, in addition to Pseudomonas aeruginosa, have gentamicin similar anti-gram positive and negative bacteria biological activity. Acute toxicity to mice than gentamicin low in vivo treatment was significantly better than gentamicin. GPA and GPB have synergistic anti-bacterial effects.